Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.49 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11737499 | 0.89 | KMT2A (0.57) | KMT2AMAPK1LMNAALDH1A1KDM4E | |
| SCHEMBL23489677 | 0.88 | ROCK2 (0.62) | KMT2AMAPK1LMNAALDH1A1KDM4E | |
| SCHEMBL10144825 | 0.85 | MAPK1 (0.67) | KMT2AMAPK1LMNAALDH1A1KDM4E | |
| SCHEMBL25004063 | 0.82 | CTSL (0.62) | HPGDL3MBTL1 | |
| Dl-Phenylalanine SCHEMBL28584723 | 0.79 | ALDH1A1 (0.53) | KMT2AMAPK1LMNAALDH1A1KDM4E | |
| SCHEMBL13257747 | 0.78 | KMT2A (0.79) | KMT2AMAPK1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL888697 | 0.76 | ALDH1A1 (0.56) | ALDH1A1 | |
| SCHEMBL10281747 | 0.76 | ALDH1A1 (0.56) | ALDH1A1 | |
| SCHEMBL888695 | 0.76 | ALDH1A1 (0.56) | ALDH1A1 | |
| SCHEMBL28547568 | 0.76 | CTSS (0.56) | KMT2AMAPK1MMP2SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230045142-A1 | SMALL MOLECULE RPN13 INHIBITORS WITH ANTITUMOR PROPERTIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230045142-A1 | SMALL MOLECULE RPN13 INHIBITORS WITH ANTITUMOR PROPERTIES | MRPS23, RPP30, RPS19 | KMT2A 2843/4885MAPK1 3361/4885LMNA 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.